Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 2 | History Defined

U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit

The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.

Reuters

FDA lays out annual COVID shot plan similar to flu

Americans will get a clearer idea of how often they’ll roll up their sleeves for COVID-19 shots when advisers to U.S. regulators meet Thursday to discuss an immunization schedule that looks more like the one used for flu.

Tribune News Service

Lisa Jarvis: Cancer vaccine hunt makes progress, finally

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna’s bivalent shot boosts antibodies against latest omicron strains in trial

Moderna Inc.’s booster shot of its bivalent vaccine sharply increased antibody levels against recent COVID-19 strains when compared to a fourth dose of its original immunization.

Tribune News Service

Moderna to supply 100 million COVID vaccines to poor countries

Moderna Inc. will provide as many as 100 million doses of COVID-19 shots that specifically target variants for vaccine alliance Gavi to distribute in lower-income countries in 2023.

Tribune News Service

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show.

Benzinga

FDA authorizes COVID omicron boosters for kids 5 and up

COVID-19 vaccine makers Pfizer Inc. and Moderna Inc. received U.S. regulatory clearances for their omicron-targeted boosters for children as young as 5.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26

Bloomberg

Benzinga

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Benzinga

Shortages of Moderna COVID-19 boosters seen in US

Some of the nation's pharmacies are reporting shortages of Moderna Inc.’s new bivalent booster shot for COVID-19 as one factory used in producing the vaccine remains offline following a safety inspection.

Tribune News Service

EU regulator approves Omicron vaccines

The European Union’s drug regulator has recommended the use of two Omicron-tailored vaccines developed by the Pfizer-BioNTech partnership and Moderna Inc ahead of a fresh booster programme this fall across the continent.

Bangkok Post

EU regulator clears tweaked versions of COVID vaccines

The European Medicines Agency has recommended the authorization of two coronavirus vaccines made by Pfizer-BioNTech and Moderna Inc., tweaked to include protection against an early version of the omicron variant

The Independent UK

FDA clears way for boosters targeted at latest COVID variants

COVID-19 boosters from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE that are tailored to the latest COVID-19 omicron variants got U.S. regulatory clearance, a move toward additional protection as concern grows about potential new waves in the fall and winter.

Tribune News Service

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

US buying $1.7 billion of Moderna’s omicron-specific booster

Moderna Inc. said it secured a $1.74 billion contract to supply the U.S. government with its new omicron-specific vaccine.

Tribune News Service

COVID shots should get omicron-targeted update, FDA advisers say

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

Benzinga

US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines

The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC:COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines. Croda will also invest up to $58 million. The investment will be used to establish a new lipid facility in Lamar,…

Tribune News Service

Moderna’s shots for children 6-17 win CDC advisers’ backing

Moderna Inc.’s COVID-19 vaccines for children and teens won support from a key panel of U.S. health advisers, a crucial step toward providing yet another tool for protecting young people from the most serious effects of the virus.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

So What's Going On With Moderna Shares Rising Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher after the company released data on its bivalent COVID booster candidate. Data showed potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5.

Benzinga

Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants

Moderna Inc (NASDAQ:MRNA) has released new clinical data on its bivalent (omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5. The company is working on completing regulatory submissions…

Benzinga

Moderna To establish New Vaccine Facility In Britain

Moderna Inc (NASDAQ:MRNA) announced an agreement with the United Kingdom government to establish an mRNA Innovation and Technology Center in the U.K. Additionally, Moderna plans to expand its presence in the U.K. through investments in R&D activities. Moderna is collaborating with the National Institute for Health Research on a Phase 3 study…

Tribune News Service

US panel backs Moderna, Pfizer COVID shots for youngest kids

Infants and toddlers in the U.S. are now able to be vaccinated against COVID-19 after shots from Moderna Inc. and Pfizer Inc. won support from health advisers on Saturday.

Tribune News Service

FDA clears Moderna, Pfizer COVID shots for children 5 and under

COVID vaccines for children ages 5 and under from Pfizer Inc. and Moderna Inc. received authorization from U.S. regulators, meaning almost all of the American population can soon get protected against COVID-19 disease.

Benzinga

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Moderna Plans COVID-19 Vaccine Trial For Infants: WSJ

Moderna Inc (NASDAQ: MRNA) is reportedly planning to evaluate its COVID-19 vaccine in infants aged three months to 6 months.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Department of Justice

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.